GlobeNewswire by notified

Islandsbanki hf.: Upcoming green bond auction 15 November

Share

Íslandsbanki hf. will be offering two new senior preferred bonds in a closed auction on Tuesday 15 November 2022.

The new series ISB GBF 27 1122 and ISB GB 27 1122 will be offered.

ISB 27 GBF 1122 is a 5-year floating rate bond series maturing on 22 November 2027. This is a green equal payment floating rate bond. The bond will be issued at a spread of 125bp over 1-month REIBOR.

ISB GB 27 1122 is a 5-year fixed rate bond series. This is a green fixed rate bond with an annual coupon of 7.70% and repayment of nominal on 22 November 2027.

The bonds will be offered for sale at the predefined price of par in the auction.

In connection with the auction holders of the series ISB 24 1125 and ISB GB 25 1126 can sell their bonds in the series against bonds bought in the above-mentioned auction. The clean price of the series ISB 24 1125 is predefined at 100.00. The clean price of the series ISB GB 25 1126 is predefined at 89.9746 (yield 7.33%).

The Bank reserves the right to accept or reject offers in part or in whole.

Expected settlement date is 22 November 2022.

The bonds will be issued under the Bank’s EMTN programme and are expected to be admitted to trading on Nasdaq Iceland on 22 November 2022.

An amount equal to the net proceeds of the issue will be used to finance or refinance, in whole or in part, the Issuer's investments in Eligible Assets (being Green Projects), as further described in the Issuer’s Sustainable Financing Framework available on the Issuer’s website: https://www.islandsbanki.is/en/product/about/funding.

The auction will be managed by Íslandsbanki’s Fixed Income Sales. Offers shall be submitted by e-mail to vbm@isb.is before 16:00 p.m. on 15 November 2022.

For further information contact Investor Relations, ir@islandsbanki.is.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Wolters Kluwer again recognized as a Leader in Gartner® Magic Quadrant™ for Financial Planning Software8.12.2023 17:50:33 CET | Press release

PRESS RELEASE Wolters Kluwer again recognized as a Leader in Gartner® Magic Quadrant™ for Financial Planning Software Wolters Kluwer CCH Tagetik AI-based financial planning solution empowers finance professionals to make faster and better-informed decisions. New York – Dec. 8, 2023 – Wolters Kluwer, a global leader in professional information, software solutions and services, today announced that it has been recognized as a Leader in the 2023 Gartner Magic Quadrant for Financial Planning Software. Earlier this month, Wolters Kluwer also received recognition as a Leader in the Gartner Magic Quadrant for Financial Close and Consolidation Software. CCH Tagetik Budgeting, Planning and Forecasting software is Wolters Kluwer’s AI-based, enterprise-wide planning solution, which helps global companies facilitate strategic, financial, and operational planning, including supply chain, workforce, and capital expenses. The solution, which supports customers across vertical industries, is particula

Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment8.12.2023 17:50:00 CET | Press release

Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programme Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (eBC) who have residual invasive disease following neoadjuvant (before surgery) treatment. A statistically significant and clinically meaningful improvement in overall survival (OS), a secondary endpoint, was observed with adjuvant (post-surgery) Kadcyla® (trastuzumab emtansine) compared to Herceptin® (trastuzumab): at the 7-year landmark OS rates were 89.07% and 84.37

Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation8.12.2023 17:45:00 CET | Press release

Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to address resistance to treatment and poor prognosis associated with PIK3CA mutations2-5 These new data are being presented today in an oral presentation at the 2023 San Antonio Breast Cancer Symposium and shared with health authorities Basel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today positive results from the Phase III INAVO120 study evaluating inavolisib in combination with palbociclib (Ibrance®) and fulvestrant as a first-line treatment for people with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.1 The inavolisib combination reduced the risk of disease worsening or death (progression-free survival; PFS) by 57% compared to palbociclib and fulvestrant alone (15.0 months vs 7.3 months;

Innofactor Plc: Share Repurchase 8.12.20238.12.2023 17:30:00 CET | Press release

Innofactor Plc Announcement 8.12.2023Innofactor Plc: Share Repurchase 8.12.2023In the Helsinki Stock ExchangeTrade date 8.12.2023Bourse trade BuyShare IFA1VAmount 4,400SharesAverage price/ share 1.1700EURTotal cost 5,148.00EURInnofactor Plc now holds a total of 580 029 sharesincluding the shares repurchased on 8.12.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 2029sami.ensio@innofactor.comwww.innofactor.com Attachment Innofactor_8.12_trades

Azerion publishes bond prospectus and applies for admission to trading of its bonds on Nasdaq Stockholm8.12.2023 17:26:44 CET | Press release

Amsterdam, 8 December 2023 – Azerion Group N.V. (the “Company”) has, on 14 September 2023, following a bookbuilding process, successfully placed EUR 165 million of senior secured floating rate bonds under a framework of EUR 300 million to qualified institutional investors internationally (the "Bonds"). The Dutch Authority for the Financial Markets (Autoriteit Financiële Markten (the “AFM”)) has on 8 December 2023 approved the prospectus in relation to the admission to trading of the Bonds (the "Prospectus"). The approval of the Prospectus has been notified to the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The Prospectus will be available on the AFM’s website (https://www.afm.nl/en/sector/registers/meldingenregisters/goedgekeurde-prospectussen) and, together with a Swedish translation of the summary of the Prospectus, on the Company’s website (https://www.azerion.com/reports/). The Company will apply for listing of the Bonds on the Corporate Bond List of Nasdaq St